Home
Live Updates
Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update : comparemela.com
Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Initiation of OPERA-01 pivotal Phase 3 monotherapy clinical trial on track; expecting to enroll first patient in fourth quarterNew clinical data for palazestrant to be presented in the fourth quarter...
Related Keywords
Cambridge ,
Cambridgeshire ,
United Kingdom ,
Berlin ,
Germany ,
Chicago ,
Illinois ,
United States ,
Spain ,
Madrid ,
San Francisco ,
California ,
Massachusetts ,
American ,
Seanp Bohen ,
Shane Kovacs ,
Ignacio Guerrero Ros ,
Aurigene Pharmaceuticals The Agreement ,
Securities Exchange ,
Breast Cancer Annual Congress ,
Nasdaq ,
American Society Of Clinical Oncology ,
Exchange Commission ,
European Society For Medical Oncology ,
Olema Pharmaceuticals Inc ,
Twitter ,
Linkedin ,
Chief Executive Officer ,
Medical Oncology ,
Clinical Oncology ,
Annual Meeting ,
European Society ,
Aurigene Pharmaceuticals ,
Aurigene Agreement ,
Securities Act ,
Securities Exchange Act ,
Quarterly Report ,
Consolidated Statements ,
Months Ended June ,
Chief Operating ,
Markets ,
comparemela.com © 2020. All Rights Reserved.